Validated RP-HPLC method for the simultaneous analysis of gemcitabine and LY-364947 in liposomal formulations.
作者： Shyam S Bansal , Christian Celia , Silvia Ferrati , Erika Zabre , Mauro Ferrari
DOI: 10.2174/13894501113149990165
关键词:
摘要: Combined use of gemcitabine (Gem) and LY-364947 (LY), a TGF-β1 receptor inhibitor, has shown promise for the treatment fibrotic pancreatic cancer, by reducing collagen production improving tumor drug penetration. The preparation optimization novel Gem LY formulations, including co-encapsulation in liposomes, require a validated method for simultaneous quantification both drugs, that had yet to be developed. Here we demonstrate an RP-HPLC protocol detection at 266 228 nm with retention times of 3.37 11.34 mins, respectively. The method, which uses C18 column KH2PO4 (10 mM)-methanol mobile phase, was validated linearity, precision, accuracy, limits detection, robustness. Co-loaded liposomes Gem and (Gem/LY liposomes) were developed investigate applicability pharmacokinetic analysis and formulation characterization. specificity was evaluated presence liposomal components fetal bovine serum (FBS). Finally, demonstrated quantifying Gem/LY encapsulation efficiency concentration liposomes-spiked FBS.
eurekaselect.com参考文章(35)
Isaac P. Witz, Tumor-microenvironment interactions: dangerous liaisons. Advances in Cancer Research. ,vol. 100, pp. 203- 229 ,(2008) , 10.1016/S0065-230X(08)00007-9
M. R. Kano, Y. Bae, C. Iwata, Y. Morishita, M. Yashiro, M. Oka, T. Fujii, A. Komuro, K. Kiyono, M. Kaminishi, K. Hirakawa, Y. Ouchi, N. Nishiyama, K. Kataoka, K. Miyazono, Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling Proceedings of the National Academy of Sciences of the United States of America. ,vol. 104, pp. 3460- 3465 ,(2007) , 10.1073/PNAS.0611660104
Kiyoshi Mori, Yukari Kamiyama, Hisashi Kasai, Tetsuro Kodama, A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer. Chemotherapy. ,vol. 58, pp. 78- 83 ,(2012) , 10.1159/000335601
Pelin Mutlu, Ali Ugur Ural, Ufuk Gündüz, Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line. Biomedicine & Pharmacotherapy. ,vol. 66, pp. 228- 231 ,(2012) , 10.1016/J.BIOPHA.2011.11.023
Brian Bierie, Harold L. Moses, Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer Nature Reviews Cancer. ,vol. 6, pp. 506- 520 ,(2006) , 10.1038/NRC1926
Melody A. Swartz, Noriho Iida, Edward W. Roberts, Sabina Sangaletti, Melissa H. Wong, Fiona E. Yull, Lisa M. Coussens, Yves A. DeClerck, Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy Cancer Research. ,vol. 72, pp. 2473- 2480 ,(2012) , 10.1158/0008-5472.CAN-12-0122
Kevin Anton, John Glod, Targeting the tumor stroma in cancer therapy. Current Pharmaceutical Biotechnology. ,vol. 10, pp. 185- 191 ,(2009) , 10.2174/138920109787315088
Sheng-Bin Peng, Lei Yan, Xiaoling Xia, Scott A. Watkins, Harold B. Brooks, Douglas Beight, David K. Herron, Michael L. Jones, John W. Lampe, William T. McMillen, Nicholas Mort, J. Scott Sawyer, Jonathan M. Yingling, Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry. ,vol. 44, pp. 2293- 2304 ,(2005) , 10.1021/BI048851X
Jonathan M. Yingling, Kerry L. Blanchard, J. Scott Sawyer, Development of TGF-β signalling inhibitors for cancer therapy Nature Reviews Drug Discovery. ,vol. 3, pp. 1011- 1022 ,(2004) , 10.1038/NRD1580
Yoshiyasu Mita, Tetsuo Ajiki, Takashi Kamigaki, Taro Okazaki, Hiroshige Hori, Hideki Horiuchi, Kenro Hirata, Tsunenori Fujita, Takahiro Fujimori, Yoshikazu Kuroda, Antitumor Effect of Gemcitabine on Orthotopically Inoculated Human Gallbladder Cancer Cells in Nude Mice Annals of Surgical Oncology. ,vol. 14, pp. 1374- 1380 ,(2007) , 10.1245/S10434-006-9191-9